Old Offer To Drop Chancery Case Roils Bioverativ Settlement
An attorney for stockholders who secured an $84 million partial settlement in a Delaware Chancery Court suit challenging biotech venture Bioverativ Inc.'s 2018 sale to Sanofi Inc. revealed in court Wednesday...To view the full article, register now.
Already a subscriber? Click here to view full article